Study Title | Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma |
---|---|
Protocol ID | SJiMB21 |
Disease (Sub Disease) | Medulloblastoma |
Diagnosis Stage | Newly diagnosed |
Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ St. Jude Children's Research Hospital |
Links | https://clinicaltrials.gov/ct2/show/NCT05535166 |
Trial Status | Preparing to Open |
Study Type | Treatment |
Phase | Phase 2 |
Age Eligibility | up to 59 Months |
International registry ID's | NCT05535166 |